Mobile non-invasive solution for liver disease management, ideal for multi-site configuration
Portable non-invasive solution for efficient liver disease management
Complete non-invasive solution for advanced liver disease management
State-of-the-art non-invasive solution for liver disease management, affordable to all
FibroScan® is the original, non-invasive solution for assessing liver fibrosis and steatosis at the point-of-care in an exam that takes as little as four minutes.
Unlike other elastography tools, FibroScan® uniquely delivers proprietary biomarkers (LSM by VCTE®, CAP, and SSM by VCTE®), recognized by clinical guidelines.
Fast, quantitative, and standardized, FibroScan® provides the clarity clinicians need to detect risk earlier, guide informed decisions, and support ongoing management using measurements relied upon worldwide.
FibroScan® exams are widely used across various specialties, including hepatology, gastroenterology, endocrinology, obesity medicine, and primary care.
Not all liver scans are the same. Why settle for less?
Validated. Proven. Exclusively FibroScan®.
The transient elastography is a non-invasive technique that measures the stiffness of liver and spleen tissue. It works by sending a mechanical pulse that generates a wave, whose speed of propagation is analysed: the stiffer the tissue, the faster the wave travels.
Only one solution truly delivers the clinical confidence providers and researchers trust. VCTE® – only available through FibroScan® – is backed by 25 years of leadership with proven performance in liver health assessment.
Vibration-controlled transient elastography is not a generic “process”— it is a proprietary technology developed, patented, and exclusively commercialised by Echosens.
Across all major guidelines, FibroScan® is named directly and exclusively as the reference technology for non-invasive liver assessment. No competing device has contributed published evidence of comparable scale or quality to guideline development.
FibroScan® biomarkers are cited in thousands of peer-reviewed studies and included in major international guidelines for MASLD/MASH and chronic liver disease.
FibroScan® is the most extensively studied solution in non-invasive liver assessment and spleen assessment. Its proprietary biomarkers—LSM by VCTE®, CAP, and SSM by VCTE®—have been evaluated, reported, and cited in more than 6,270 peer-reviewed publications and nearly 250 international guidelines. Clinical validation of FibroScan® spans all major chronic liver diseases and patient morphologies, including populations where other non-invasive tests show reduced accuracy.
FibroScan® is directly cited in major European and U.S. clinical practice guidelines, including AASLD, AACE, AGA and EASL, as the preferred non-invasive test in patients with MASLD/MASH.
Easy to perform, comfortable for patients, and designed for real-world workflows.
A FibroScan® examination is quick and painless. The exam is typically completed in four minutes or less, with results available immediately for point-of-care decision-making.
FibroScan® is designed to be easy to use—whether in a clinic, hospital, or high-volume practice. Any trained operator can perform the exam, with minimal learning curve and no imaging background required.
Advanced FibroScan® systems feature Guided VCTE®, a next-generation enhancement that provides real-time visual indicators to help guide operators to the optimal measurement location. Guided VCTE® supports consistent performance across all adult morphologies, including patients with BMI ≥ 35, ensuring quicker and more confident measurements in diverse populations.
From onboarding to everyday use, FibroScan® customers gain access to clinical, technical, and educational support designed for long-term success.
When you adopt FibroScan®, you gain more than a device—you gain a long-term partner in metabolic liver health. FibroScan® customers receive ongoing support from dedicated clinical, service, and market access teams to help drive efficient implementation and sustained clinical success.
Our Clinical Application Specialists provide personalised onboarding, hands-on training, and workflow optimisation guidance so that every team member—from physicians to clinical support staff—feels confident using FibroScan®.
To support skills development over time, Echosens offers a wide range of training resources, including:
To enhance the productivity of our customers, Echosens Technical Support you with a full range of services: technical support, probe calibrations, preventative maintenance, and curative maintenance.
This comprehensive ecosystem helps ensure optimal system performance, consistent examination quality, and a smooth experience for both clinicians and patients.
FibroScan® supports risk assessment, staging, and monitoring of liver disease across primary care, endocrinology, gastroenterology, hepatology, and obesity medicine.
Beyond FibroScan®, Echosens develops solutions to optimize the management of liver diseases and assist in guiding treatment decisions.
* SSM is a marker for non-invasive evaluation of spleen stiffness which has been used in a clinical setting to assess portal hypertension and for variceal surveillance.
Products in the FibroScan® range are class IIa medical devices according to Rule 10 of ANNEX VIII of Regulation EU 2017/745 (CE 0459) and are manufactured by Echosens™. FibroScan® devices are intended to provide: Liver stiffness measurements at a shear wave frequency of 50 Hz, liver ultrasound attenuation measurements (CAP: Controlled Attenuation Parameter) at 3.5 MHz and spleen stiffness measurements at a shear wave frequency of 100 Hz (FibroScan® 630 Expert only). These non-invasive devices are intended to aid clinical management, diagnosis, and monitoring of patients with confirmed or suspected chronic liver disease, as part of an overall assessment of the liver. FibroScan® devices may aid the healthcare professionals in the assessment of liver fibrosis, steatosis, and in determining the likelihood of cirrhosis, and its complications (FibroScan® 630 Expert only). They are used, in conjunction with other clinical and laboratory data, during liver assessment in patients with confirmed or suspected chronic liver disease. Examinations with FibroScan® devices shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.
